SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.
Malaria treatment: Halofantrine
Read more from SRI
-
SRI earns FDA Orphan Drug Designation for pancreatic cancer
The designation accelerates clinical development of SRI’s TALL® immunotherapy and brings more affordable therapies to market faster. SRI’s Targeted Antigen Loaded Liposomes (TALL) — a treatment that expands the benefits of immunotherapy such as check-point inhibitors — has been granted Orphan Drug Designation (ODD) for pancreatic ductal adenocarcinoma (PDAC) by the U.S. Federal Drug Administration (FDA). As a result,…
-
Podcast: A reading intervention for struggling adolescent students
The SERP Institute’s Margaret Troyer and Kala Jones discuss a research-based reading program that helps older students turn the page.
-
SRI researchers watched over 1000 YouTube videos for kids, and this is what they learned
Most YouTube videos intended to teach early literacy and math don’t use characters or narratives, according to recent SRI research.